… performance status (PS) 0–1 since it has been shown to be superior to single agent treatment
and marginally superior to non-platinum combinations in terms of overall survival [2], [3]. …

… trials were analyzed to evaluate prognostic factors and treatment selection in the first-line
management of advanced non-small cell lung cancer patients with performance status (PS) 2. …

… Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell
lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- …

Purpose To compare single-agent pemetrexed (P) versus the combination of carboplatin and
pemetrexed (CP) in first-line therapy for patients with advanced non–small-cell lung cancer …

… study of recurrent or metastatic gastric cancer patients with poor performance status. In
conclusion, first-line single-agent palliative chemotherapy is tolerated and has a relatively good …

… The clinical characteristics were matched for performance status, age and tumor stage. All
… plus single agents versus same single agents and two trials compared single agents versus …

… (NSCLC) and good performance status (PS).Randomized studies have … ) as single-agent
therapy for patients with advanced NSCLC who have progressive disease after platinum agent–…

… Elderly patients with advanced non-small-cell lung cancer (NSCLC) with poor performance
status (PS) are a special population requiring particular attention. Single-agent oral …

… was most marked in patients with performance status 3. … chemotherapy to patients with good
performance status (PS), … benefit in patients treated with single-agent vinorelbine (VIN) over …

… Group performance status of 0 or I. Actual … with other active single agents. The regimen …
has proven activity when used as a single agent in advanced NSCLC.10-13 It also has shown …